Janus Henderson Group PLC Purchases 155,259 Shares of CARGO Therapeutics, Inc. (NASDAQ:CRGX)

Janus Henderson Group PLC lifted its position in CARGO Therapeutics, Inc. (NASDAQ:CRGX) by 5.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,830,544 shares of the company’s stock after buying an additional 155,259 shares during the period. Janus Henderson Group PLC owned about 6.15% of CARGO Therapeutics worth $40,859,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Brooklyn Investment Group bought a new position in shares of CARGO Therapeutics in the fourth quarter worth approximately $27,000. Tower Research Capital LLC TRC lifted its stake in shares of CARGO Therapeutics by 565.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,800 shares of the company’s stock worth $84,000 after buying an additional 4,929 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of CARGO Therapeutics in the fourth quarter worth approximately $141,000. Invesco Ltd. bought a new position in shares of CARGO Therapeutics in the fourth quarter worth approximately $165,000. Finally, Intech Investment Management LLC bought a new position in shares of CARGO Therapeutics in the fourth quarter worth approximately $181,000. Institutional investors own 93.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CRGX shares. Truist Financial downgraded shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $32.00 to $7.00 in a research report on Thursday, January 30th. Jefferies Financial Group downgraded shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $32.00 to $3.00 in a research report on Thursday, January 30th. HC Wainwright downgraded shares of CARGO Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, January 30th. JPMorgan Chase & Co. downgraded shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a research report on Thursday, January 30th. Finally, William Blair downgraded shares of CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company. Based on data from MarketBeat, CARGO Therapeutics has a consensus rating of “Hold” and a consensus target price of $15.00.

CARGO Therapeutics Trading Down 3.3%

Shares of CRGX stock opened at $3.84 on Thursday. CARGO Therapeutics, Inc. has a 12 month low of $3.00 and a 12 month high of $25.45. The stock has a market cap of $177.06 million, a P/E ratio of -0.90 and a beta of 0.47. The company has a 50 day simple moving average of $4.22 and a two-hundred day simple moving average of $9.69.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.